Hyaluronan concentration and molecular mass in psoriatic arthritis: biomarkers of disease severity, resistance to treatment, and outcome

Autor:	Anders Larsson, Urban Hellman, Anna Engström-Laurent, Ulla Lindqvist
Rok vydání:	2019
Předmět:	Adult Male medicine.medical_specialty medicine.medical_treatment Immunology Drug Resistance Arthritis Severity of Illness Index Chemistry Techniques Analytical 03 medical and health sciences Psoriatic arthritis 0302 clinical medicine Rheumatology Disease severity Internal medicine Severity of illness medicine Humans Immunology and Allergy 030212 general & internal medicine Hyaluronic Acid Treatment resistance Correlation of Data Skin Rheumatology and Autoimmunity 030203 arthritis & rheumatology Reumatologi och inflammation integumentary system Molecular mass Tumor Necrosis Factor-alpha business.industry Arthritis Psoriatic Adalimumab Patient Acuity food and beverages General Medicine Middle Aged medicine.disease Treatment Outcome Cytokine Antirheumatic Agents Female business Biomarkers
Zdroj:	Scandinavian Journal of Rheumatology. 48:284-293
ISSN:	1502-7732 0300-9742
DOI:	10.1080/03009742.2019.1577490
Popis:	Objective: Low molecular mass hyaluronan causes inflammatory processes and can act as a pro-inflammatory cytokine in skin and other sites of activity in psoriatic arthritis (PsA). This study investigated whether the molecular mass distribution of hyaluronan (HA) in skin and the quantity of circulating HA are related to the clinical inflammatory picture in PsA with active disease and to the effect of treatment with anti-tumour necrosis factor-α (anti-TNF-α) adalimumab. Methods: Twenty patients with TNF-α-naïve active polyarticular PsA were included in this prospective clinical trial of treatment with 40 mg s.c. adalimumab according to standard procedure. Clinical activity, patients’ assessments, and skin biopsies were captured at inclusion and at the 12 week follow-up. Ten healthy individuals were recruited for comparison of HA analyses. Histochemistry of skin inflammation, serum HA, and molecular mass of HA were determined. Results: Overall improvements in clinical parameters were observed. Eight of 18 patients reached minimum disease activity after 12 weeks and disease activity was significantly reduced (p
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa32c6041c120bf0bc2639f0970894a2 https://doi.org/10.1080/03009742.2019.1577490 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.